[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648109":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":45,"collaborators":24,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":24,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":24,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":24,"overallStatus":67,"whyStopped":24,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","Period 1 : Reference drug(AD-1181), Period 2 : Test drug(AD-118) Single-dose oral administration of AD-1181 in Period 1, followed by single-dose oral administration of AD-118 in Period 2.",[13],"Drug: AD-118, AD-1181",{"label":15,"type":10,"description":16,"interventionNames":17},"Sequence B","Period 1 : Test drug(AD-118), Period 2 : Reference drug(AD-1181) Single-dose oral administration of AD-118 in Period 1, followed by single-dose oral administration of AD-1181 in Period 2.",[13],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","AD-118, AD-1181","Single-dose oral administration of AD-118, according to randomized treatment sequence in a 2-period crossover design.",[9,15],null,{"type":20,"name":21,"description":26,"armGroupLabels":27,"otherNames":24},"Single-dose oral administration of AD-1181, according to randomized treatment sequence in a 2-period crossover design.",[9,15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"JaeHun Jung","CONTACT","+82-31-891-5683","jhjung@addpharma.co.kr",[35],{"facility":36,"status":24,"city":37,"state":24,"zip":24,"country":38,"countryCode":24,"cosmosGeoPoint":39,"geoPoint":44,"contacts":24},"H Plus Yangji Hospital","Seoul","South Korea",{"type":40,"coordinates":41},"Point",[42,43],126.9784,37.566,{"lat":43,"lon":42},{"type":46,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100648109","phase-1-a-study-to-evaluate-the-safety-pharmacokinetics-of-ad-118-and-ad-1181-in-healthy-adult-subjects-100648109",false,"NCT07717749","A Study to Evaluate the Safety, Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-118 Compared to AD-1181 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* Subjects aged 19 years or older and under 65 years at the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years","64 Years",{"count":59,"type":60},74,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1","A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 Under Fasted Conditions in Healthy Adult Subjects",[66],"Chronic Heart Failure","NOT_YET_RECRUITING","2026-07-16",{"date":70,"type":71},"2026-07-21","ACTUAL",{"date":73,"type":60},"2026-07-24",{"date":75,"type":60},"2026-08",{"name":5,"class":6},1]